Follow
'In an 822-patient clinical trial published Wednesday in the New England Journal of Medicine, Xu’s antiviral, VV116, appeared just as effective as Paxlovid at easing patient’s symptoms. Newly diagnosed patients who took VV116 recovered after a median of 4 days, compared with 5 days for Paxlovid, though experts caution that the study was not large enough to say one was better than the other.'
https://www.statnews.com/2022/12/28/chinese-developed-alternative-to-paxlovid/
@cyrilpedia that’s interesting the data look good